This year’s Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases goes to Kristine Yaffe of the University of California, San Francisco, and Claudia Kawas of the University of California, Irvine. These two pioneers in the epidemiology of dementia will share the $100,000 prize, which is made possible by the Potamkin Family Foundation of Miami Lakes, Florida, and rewards contributions to research in neurodegenerative disease. Yaffe and Kawas will be honored at the 69th annual American Academy of Neurology meeting, held April 22 to 28 in Boston.

Kristine Yaffe

Despite the hundreds of publications Yaffe has churned out so far, a central theme emerges from her work, and it is that a sizable portion of the dementia burden in the world is preventable. Yaffe has uncovered myriad modifiable risk factors for dementia. Findings published throughout the span of her career have helped untangle the complex relationship between estrogen replacement therapy and cognitive decline (see Yaffe et al., 1998Yaffe et al., 2005; Whitmer et al., 2011). Her work has exposed cognitive dangers of high cholesterol, cardiovascular and metabolic syndromes such as diabetes and midlife obesity, as well as sleep disorders and lack of exercise (see Mar 2002 newsNov 2004 newsResearch TimelineAug 2011 news; and Jul 2011 news). Her studies on thousands of military veterans have linked dementia to head trauma or post-traumatic stress disorder (see Yaffe et al., 2010Jun 2014 news). Yaffe’s work sends the message that millions of dementia cases could be prevented through behavioral and lifestyle changes (see Jul 2011 news on Barnes and Yaffe, 2011, and Norton et al., 2014). 

Claudia Kawas

As a geriatric neurologist, Kawas has focused on defining the unique factors that influence dementia in people over the age of 90. Long before studying the oldest old became fashionable, Kawas started the 90-plus study of nonagenarians and centenarians (see Kawas, 2008). This seminal project has yielded dozens of analyses about this rapidly growing demographic. Her studies retired the old idea that dementia levels plateau after a certain age, finding that dementia risk still doubles every five years even in the oldest old, just as it does starting in a person’s 60s (see Corrada et al., 2010). While initial findings from 90-plus pointed to a disconnect between amyloid and tau pathology at autopsy and dementia, subsequent work concluded the opposite (see Robinson et al., 2011; Jan 2012 Alzforum webinar). 

Kawas has also linked decreases in synaptophysin to dementia in the oldest old, as well as risk factors including inflammation, visual memory impairment, and hypertension (see Head et al., 2009; Kravitz et al., 2009; Kawas et al., 2003; Corrada et al., 2017). 

Both Yaffe and Kawas have contributed generously to discussions and commentary on Alzforum over the years. We thank them and heartily congratulate them on this prize.—Jessica Shugart

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

News Citations

  1. Cholesterol Again Linked with Alzheimer's
  2. Study Links Metabolic Syndrome, Inflammation to Cognitive Decline
  3. Breathe Deep—Nighttime Oxygen Loss Linked to Dementia
  4. Exercise and the Brain: More Support for Protective Effects
  5. Brain Injury Boosts Dementia Risk
  6. A Paradigm Shift for Treating Depression in Alzheimer’s?

Webinar Citations

  1. AD in the Oldest Old—What Does Aβ Have to Do With It?

Paper Citations

  1. . Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998 Mar 4;279(9):688-95. PubMed.
  2. . Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005 Apr;162(4):683-90. PubMed.
  3. . Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol. 2011 Jan;69(1):163-9. PubMed.
  4. . Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry. 2010 Jun;67(6):608-13. PubMed.
  5. . The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011 Sep;10(9):819-28. PubMed.
  6. . Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014 Aug;13(8):788-94. PubMed.
  7. . The oldest old and the 90+ Study. Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S56-9. PubMed.
  8. . Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010 Jan;67(1):114-21. PubMed.
  9. . Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old. Brain. 2011 Dec;134(Pt 12):3708-15. PubMed.
  10. . Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol Aging. 2009 Jul;30(7):1125-34. PubMed.
  11. . Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement. 2009 Jul;5(4):318-23. PubMed.
  12. . Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology. 2003 Apr 8;60(7):1089-93. PubMed.
  13. . Age of onset of hypertension and risk of dementia in the oldest-old: The 90+ Study. Alzheimers Dement. 2017 Feb;13(2):103-110. Epub 2017 Jan 17 PubMed.

Other Citations

  1. Research Timeline

Further Reading

No Available Further Reading